KR100487887B1 - East extract relaxing premenstrual sydrome and menstrual pain, compositions containing the same, and preparation thereof - Google Patents
East extract relaxing premenstrual sydrome and menstrual pain, compositions containing the same, and preparation thereof Download PDFInfo
- Publication number
- KR100487887B1 KR100487887B1 KR10-2001-0026208A KR20010026208A KR100487887B1 KR 100487887 B1 KR100487887 B1 KR 100487887B1 KR 20010026208 A KR20010026208 A KR 20010026208A KR 100487887 B1 KR100487887 B1 KR 100487887B1
- Authority
- KR
- South Korea
- Prior art keywords
- dysmenorrhea
- yeast
- pms
- yeast extract
- composition
- Prior art date
Links
- 208000005171 Dysmenorrhea Diseases 0.000 title claims abstract description 67
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 239000000284 extract Substances 0.000 title abstract 2
- 230000002040 relaxant effect Effects 0.000 title 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims abstract description 65
- 239000012138 yeast extract Substances 0.000 claims abstract description 63
- 229940041514 candida albicans extract Drugs 0.000 claims abstract description 60
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 33
- 229920001661 Chitosan Polymers 0.000 claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 claims abstract description 15
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 12
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 12
- 235000008434 ginseng Nutrition 0.000 claims abstract description 12
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 8
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 8
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 8
- 229940010454 licorice Drugs 0.000 claims abstract description 8
- 240000002045 Guettarda speciosa Species 0.000 claims abstract description 6
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 6
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 6
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 5
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 5
- 235000008397 ginger Nutrition 0.000 claims abstract description 5
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims abstract description 4
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 4
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims description 24
- 239000006228 supernatant Substances 0.000 claims description 10
- 108091005804 Peptidases Proteins 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 6
- 241000411851 herbal medicine Species 0.000 claims description 6
- 102000035195 Peptidases Human genes 0.000 claims description 5
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 claims description 5
- 108010058643 Fungal Proteins Proteins 0.000 claims description 4
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 4
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 4
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000003698 anagen phase Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 abstract description 53
- 230000000694 effects Effects 0.000 abstract description 32
- 239000002775 capsule Substances 0.000 abstract description 25
- 235000013305 food Nutrition 0.000 abstract description 11
- 239000004615 ingredient Substances 0.000 abstract description 9
- 230000036541 health Effects 0.000 abstract description 6
- 244000163122 Curcuma domestica Species 0.000 abstract description 5
- 235000003392 Curcuma domestica Nutrition 0.000 abstract description 5
- 244000246386 Mentha pulegium Species 0.000 abstract description 5
- 235000016257 Mentha pulegium Nutrition 0.000 abstract description 5
- 235000004357 Mentha x piperita Nutrition 0.000 abstract description 5
- 235000003373 curcuma longa Nutrition 0.000 abstract description 5
- 235000001050 hortel pimenta Nutrition 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 5
- 235000013976 turmeric Nutrition 0.000 abstract description 5
- 235000009508 confectionery Nutrition 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 235000013376 functional food Nutrition 0.000 abstract description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 235000013361 beverage Nutrition 0.000 abstract 1
- 230000003203 everyday effect Effects 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 34
- 230000036407 pain Effects 0.000 description 34
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 26
- 230000005906 menstruation Effects 0.000 description 26
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 23
- 208000024891 symptom Diseases 0.000 description 23
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 18
- 230000008859 change Effects 0.000 description 12
- 239000002858 neurotransmitter agent Substances 0.000 description 11
- 229940076279 serotonin Drugs 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 11
- 229940088597 hormone Drugs 0.000 description 10
- 239000005556 hormone Substances 0.000 description 10
- 241000208340 Araliaceae Species 0.000 description 9
- 229960003387 progesterone Drugs 0.000 description 9
- 239000000186 progesterone Substances 0.000 description 9
- 208000008035 Back Pain Diseases 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000000202 analgesic effect Effects 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 150000003180 prostaglandins Chemical class 0.000 description 8
- 230000035882 stress Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000037406 food intake Effects 0.000 description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 description 7
- 239000011707 mineral Substances 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 208000008930 Low Back Pain Diseases 0.000 description 6
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 229960001231 choline Drugs 0.000 description 6
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 6
- 229960003987 melatonin Drugs 0.000 description 6
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 6
- 230000002175 menstrual effect Effects 0.000 description 6
- 239000000712 neurohormone Substances 0.000 description 6
- 230000027758 ovulation cycle Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 5
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 5
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 208000002173 dizziness Diseases 0.000 description 5
- 230000002996 emotional effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229960003512 nicotinic acid Drugs 0.000 description 5
- 235000001968 nicotinic acid Nutrition 0.000 description 5
- 239000011664 nicotinic acid Substances 0.000 description 5
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 235000019157 thiamine Nutrition 0.000 description 5
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 5
- 229960003495 thiamine Drugs 0.000 description 5
- 239000011721 thiamine Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 241001072909 Salvia Species 0.000 description 4
- 235000017276 Salvia Nutrition 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 230000002180 anti-stress Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 102000008434 neuropeptide hormone activity proteins Human genes 0.000 description 4
- 108040002669 neuropeptide hormone activity proteins Proteins 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 235000019156 vitamin B Nutrition 0.000 description 4
- 239000011720 vitamin B Substances 0.000 description 4
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010029216 Nervousness Diseases 0.000 description 3
- 108090000189 Neuropeptides Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 208000013404 behavioral symptom Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 210000004246 corpus luteum Anatomy 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000006049 herbal material Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229940011671 vitamin b6 Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 2
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 2
- 206010034568 Peripheral coldness Diseases 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 229940013640 flavin mononucleotide Drugs 0.000 description 2
- 239000011768 flavin mononucleotide Substances 0.000 description 2
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 2
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229950006238 nadide Drugs 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229940124583 pain medication Drugs 0.000 description 2
- 239000003016 pheromone Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 229940046001 vitamin b complex Drugs 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 239000007218 ym medium Substances 0.000 description 2
- WPKQYFUSPONRAT-BXXNOCLASA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-5-amino-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hy Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 WPKQYFUSPONRAT-BXXNOCLASA-N 0.000 description 1
- IGACZQNUZMBGFX-AQJXLSMYSA-N 2-[[(2s)-1-[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-3-hydroxy-2-[[(2s)-2-[[(2s)-3-(1h-imidazol-5-yl)-2-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)p Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 IGACZQNUZMBGFX-AQJXLSMYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000084 Abdominal pain lower Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- PPHTYZVEJKXMNS-PVEGFDORSA-N CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O Chemical compound CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O PPHTYZVEJKXMNS-PVEGFDORSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 206010016275 Fear Diseases 0.000 description 1
- 206010016322 Feeling abnormal Diseases 0.000 description 1
- 206010016326 Feeling cold Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000037490 Medically Unexplained Symptoms Diseases 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 206010053156 Musculoskeletal discomfort Diseases 0.000 description 1
- SNIXRMIHFOIVBB-UHFFFAOYSA-N N-Hydroxyl-tryptamine Chemical compound C1=CC=C2C(CCNO)=CNC2=C1 SNIXRMIHFOIVBB-UHFFFAOYSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000500840 Spondyliosoma cantharus Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000003056 Vitamin B6 deficiency Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000009247 menarche Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000009914 physiological arousal Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 125000003748 selenium group Chemical group *[Se]* 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000000053 special nutrition Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000008939 stimulatory process Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/218—Yeast extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/11—Preparation or pretreatment of starting material involving culturing conditions, e.g. cultivation in the dark or under defined water stress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 여성의 월경전기증후군(premenstrual syndrome, PMS) 개선 및 월경통 완화에 유용한 조성물 및 그 제조 방법에 관한 것으로, 더욱 상세하게는, 건강 기능성 식품소재로 허가된 효모를 가수분해하여 얻은 효모추출물을 주원료로 하여, 키토산, 당귀, 단삼, 울금, 감초, 봉출, 박하, 계피, 박하, 생강, 인삼, 천마, 천궁, 백출 등의 생약재료를 첨가하여 혼합하고, 이것을 캡슐 또는 정의 형태로 섭취하거나, 음료의 형태로 섭취하도록 한 것을 특징으로 하는 여성의 월경전기증후군 개선 및 생리통 완화에 유용한 조성물 및 그 제조방법에 관한 것이다.The present invention relates to a composition useful for improving premenstrual syndrome (PMS) and alleviating dysmenorrhea in women, and more particularly, to a yeast extract obtained by hydrolyzing a yeast approved as a health functional food material. As a main raw material, chitosan, Angelica, sweet ginseng, turmeric, licorice, extract, peppermint, cinnamon, peppermint, ginger, ginseng, Cheonma, Cheongung, Baekchul, and other herbal ingredients are added and mixed, and these are ingested in the form of capsules or tablets, The present invention relates to a composition useful for improving premenstrual syndrome and relieving menstrual cramps for women, characterized in that it is ingested in the form of a beverage and a method of manufacturing the same.
효모 추출물의 이러한 새로운 용도는, PMS나 월경통에 있어서, 내성이나 부작용이 없고 안전성이 보장된 식품으로서의 효모 추출물을 의사나 약사의 처방없이 간편하게 구입, 섭취할 수 있게 함으로써, 일상 생활 속에서 PMS 나 월경통을 간단하게 완화시킬 수 있게 한다.This new use of yeast extract is a PMS or dysmenorrhea in everyday life by allowing the user to easily purchase and consume yeast extract as a food that has no resistance or side effects and is safe in the PMS or dysmenorrhea without a doctor or pharmacist's prescription. It can be easily alleviated.
Description
본 발명은 여성의 월경전기증후군(premenstrual syndrome, PMS) 개선 및 월경통 완화에 유용한 조성물 및 그 제조 방법에 관한 것으로, 더욱 상세하게는, 건강 기능성 식품소재로 허가된 효모를 가수분해하여 얻은 효모추출물을 주원료로 하여, 키토산, 당귀, 단삼, 울금, 감초, 봉출, 박하, 계피, 박하, 생강, 인삼, 천마, 천궁, 백출 등의 생약재료를 첨가하여 혼합한 것을 특징으로 하는 여성의 월경전기증후군 개선 및 생리통 완화에 유용한 조성물 및 그 제조방법에 관한 것이다.The present invention relates to a composition useful for improving premenstrual syndrome (PMS) and alleviating dysmenorrhea in women, and more particularly, to a yeast extract obtained by hydrolyzing a yeast approved as a health functional food material. Improvement of premenstrual syndrome in women characterized by adding and mixing herbal ingredients such as chitosan, Angelica, Salvia, Salvia, Licorice, Licorice, Mint, Cinnamon, Peppermint, Ginger, Ginseng, Cheonma, Cheongung, Baekchul And compositions useful for alleviating menstrual cramps and methods of making the same.
월경 전기 증후군(PMS)이란 여성의 월경 주기와 연관되어, 가임기 여성에게서 배란 뒤의 월경 주기 동안 나타나는 육체적 그리고 정신적 이상 현상을 말한다. 육체적 증상으로는 복통, 요통, 골반통, 복부 팽만, 설사, 변비, 유방이 딱딱해짐 등이 나타나며, 정신적 증상으로는 불안, 짜증, 우울증, 불면, 피로, 집중력 상실, 자살 충동 등이 나타난다. 이러한 증상은 여성 인구의 70%가 해당하며 이중 20%가 심각한 증상을 가지고 있어 이로 인한 여성의 활동 손실로 야기되는 사회, 경제적 손실 또한 매우 크다. Premenstrual syndrome (PMS) refers to physical and mental abnormalities that occur during the menstrual cycle after ovulation in women of childbearing age, associated with the menstrual cycle of women. Physical symptoms include abdominal pain, back pain, pelvic pain, abdominal distension, diarrhea, constipation, and stiff breasts. Mental symptoms include anxiety, irritability, depression, insomnia, fatigue, loss of concentration, and suicidal thoughts. These symptoms account for 70% of the female population, 20% of which are serious and the social and economic losses caused by women's loss of activity are also significant.
또한 월경통은, 월경 전기 증후군과 함께 대부분의 여성이 겪는 것으로, 월경 기간 혹은 월경 전후에 가볍게 또는 극심하게 나타나는 하복부통증 또는 요통을 말한다. 월경통은 가임 여성의 약 50%에서 나타나는 아주 흔한 부인과 질환의 하나다. 월경통은 주로 젊은 여성들이 겪게 되는데 초경 후 1∼2년 내에 나타나는 것이 보통 이지만, 심한 경우는 40대까지도 지속될 수 있다. 이 중에서 10% 가량은 매달 1∼3일간 평상시 하던 일을 할 수 없을 정도로 통증을 호소한다고 한다. 경희의료원 한방병원이 조사한 결과 월경시 복통과 요통, 심지어 두통 같은 통증을 호소하는 여성은 47%, 식욕부진과 소화불량 같은 위장장애 13%, 불쾌감을 느끼는 여성은 8%로 나타났다. 특히 중고등학교 여학생은 632명 가운데 70%가량이 생리통을 호소하고 50%가량은 아주 심한 통증을 호소했다. 여학생들의 통증이 더 심한 것은 과도한 학업과 시험 공포가 원인인 것으로 분석됐다. 그러나 66%가 그냥 참고 28%는 진통제로 해결해 90% 이상이 근본적인 치료를 하지 않고 있는 것으로 조사되었다.In addition, dysmenorrhea, which is experienced by most women with premenstrual syndrome, refers to lower abdominal pain or low back pain that occurs lightly or severely during or after menstruation. Menstrual pain is one of the most common gynecological disorders in about 50% of women of childbearing age. Menstrual pain usually occurs in young women, usually within one to two years after menarche, but severe cases can last up to the age of 40. About 10% of them complain of pain that they can't do their usual work for one to three days every month. A survey by Kyunghee Medical Center Oriental Medicine Hospital showed that 47% of women complained of pain such as menstrual abdominal pain, low back pain and even headache, 13% of gastrointestinal disorders such as anorexia and indigestion, and 8% of women who felt unpleasant. In particular, 70% of the 632 high school girls complained of dysmenorrhea and 50% complained of severe pain. More pain in female students was attributed to excessive academic and test fears. However, 66% of them just refer to 28% of painkillers, and more than 90% of them do not have a basic treatment.
PMS나 월경통의 정확한 원인은 상당한 기간 동안 이에 대해 많은 학자들이 연구하여 왔지만 아직 정확한 원인은 밝혀지지 않은 상태이다. 하지만 PMS나 월경통이 월경 주기와 연관되어 있다는 사실에서 내분비 호르몬의 불균형과 깊은 관련이 있다고 할 수 있다. The exact cause of PMS or dysmenorrhea has been studied by many scholars for a considerable period of time, but the exact cause is still unknown. However, the fact that PMS or dysmenorrhea is associated with the menstrual cycle suggests that the endocrine hormone imbalance is deeply related.
PMS 및 월경통의 병인에 관하여는 여러 이론들이 있는데, 그 중에는, 프로게스테론 결핍이 원인이라고 하는 이론, 에스트로겐 및 안드로겐의 과다분비가 원인이라고 하는 이론, 통증 유발 물질인 프로스타글란딘의 과다 분비가 원인이라고 하는 이론, 그리고 비타민 B 복합체 또는 필수 지방산 등의 영양결핍이 그 원인이라고 하는 이론 등이 있으며, 일반적으로 상기의 요인들이 복합적으로 작용하거나, 거기에 환경적인 요인이 더해져서 PMS 및 월경통이 발생하는 것으로 생각되어 지고 있다.There are several theories regarding the pathogenesis of PMS and dysmenorrhea, including the theory that the progesterone deficiency is the cause, the theory that the excessive secretion of estrogens and androgens is the cause, the theory that the excessive production of pain-producing prostaglandins, There is a theory that nutritional deficiency such as vitamin B complex or essential fatty acid is the cause, and in general, it is thought that PMS and dysmenorrhea occur because the above factors are combined or environmental factors are added. have.
상기 이론들 중, 가장 유력한 이론인 프로스타글란딘의 과다 분비로 인해 PMS나 월경통이 발생된다는 이론은, 월경 주기에 따르는 여성 호르몬의 분비에 있어서, 황체 형성 호르몬(프로게스테론)의 분비가 중지되면 통증 유발 물질인 프로스타글란딘이 분비되어 자궁근이 심하게 축소되고 국소 빈혈이 일어나서 통증을 느끼게 된다는 것이다. 따라서 이러한 통증이나 여러 PMS 증상을 억제하기 위하여 다음과 같은 방법이 사용되고 있다. Of these theories, PMS or dysmenorrhea occur due to excessive secretion of prostaglandins, the most prominent theory of which is a pain-inducing substance when the release of progesterone (progesterone) is stopped in the secretion of female hormones along the menstrual cycle. Prostaglandins are secreted and the uterine muscles are severely reduced and ischemia causes pain. Therefore, the following methods are used to suppress such pain and various PMS symptoms.
가장 통상적인 방법은, 아스피린, 이부프로펜 등을 사용한 프로스타글란딘의 생성 억제를 통한 통증 완화 방법이며, 또 다른 방법은 벤조디아제핀과 같은 항 불안, 항 우울증 제제를 사용하는 방법이고, 또 다른 방법은 월경 주기의 황체 형성 단계에서 프로게스테론을 투여하는 방법이 있다. The most common method is pain relief by inhibiting the production of prostaglandins using aspirin, ibuprofen, etc. Another method is to use anti-anxiety, anti-depressant agents such as benzodiazepines, and another method is the corpus luteum of the menstrual cycle. There is a method of administering progesterone in the formation step.
또한 공지된 또 다른 치료법으로는, 대한민국 특허 제0171408호에서 개시된 멜라토닌(N-아세틸-5-메톡시트립타민)을 투여하는 방법, 그리고 대한민국 공개특허 공보 특2001-0024462호에서 공개된 세로토닌(5-히드록시트립타민)을 투여하는 방법 등이 있다. Further known treatments include the method of administering melatonin (N-acetyl-5-methoxytrytamine) disclosed in Korean Patent No. 0171408, and serotonin (5) disclosed in Korean Patent Application Laid-Open No. 2001-0024462. Hydroxytryptamine).
상기 방법들 중 프로게스테론, 멜라토닌, 세로토닌과 같은 호르몬이나 신경 전달물질을 황체 형성 단계 동안 투여하는 방법들은, PMS나 월경통 뿐만 아니라 전반적인 통증 완화 그리고 만성 피로, 우울증 등을 개선하는 것으로 알려져 있다.Of these methods, methods of administering hormones or neurotransmitters such as progesterone, melatonin, and serotonin during the corpus luteum formation phase are known to improve not only PMS or dysmenorrhea, but also general pain relief and chronic fatigue, depression, and the like.
하지만, 상기와 같은 방법들은 호르몬이나 멜라토닌, 세로토닌을 직접 투여하므로, 그 안전성을 100% 확신할 수 없으며, 제조 단가가 높아서, 쉽게 상시 복용할 수 없다는 단점이 있었다.However, since the above methods directly administer hormones, melatonin, and serotonin, they cannot be 100% convinced of their safety, and have high manufacturing costs, so they cannot be easily taken at all times.
따라서, 본 발명에서는, 프로게스테론과 같은 호르몬이나 멜라토닌, 세로토닌 등을 투여하는 대신, 상용적으로 통용되고 안정성이 입증된 식품 재료를 원료로 하여 PMS나 월경통 완화 효과를 얻을 수 있는 조성물 및 그 제조 방법을 제공하는 것을 목적으로 한다. Therefore, in the present invention, instead of administering hormones such as progesterone, melatonin, serotonin, and the like, a composition and a method for preparing the composition and a method for producing a PMS or dysmenorrhea relief effect using a commercially available and proven food material as a raw material It aims to provide.
상기와 같은 목적을 달성하기 위하여, 본 발명에서는, In order to achieve the above object, in the present invention,
효모에서 추출된 것을 특징으로 하는 PMS 및 월경통 완화 기능을 갖는 효모 추출물을 제공한다. 이 때, 효모를 35℃ 내지 70℃의 온도에서 자가소화시키는 것이 바람직하며, 효모를 자가소화시킴과 동시에 또는 자가소화시킨 후에, 단백질 분해효소로 단백질을 가수분해시키는 것이 바람직하다. 또한, 이 때, 효모를 가수분해시킨 것을 원심분리하여 상등액만을 취할 수 있다.It provides a yeast extract having PMS and dysmenorrhea relief, characterized in that it is extracted from yeast. At this time, the yeast is preferably autodigested at a temperature of 35 ° C to 70 ° C, and it is preferable to hydrolyze the protein with proteolytic enzymes simultaneously with or autodigesting the yeast. At this time, only the supernatant can be taken by centrifuging the hydrolyzed yeast.
또한, 상기와 같은 목적을 달성하기 위하여 본 발명은, In addition, the present invention to achieve the above object,
상기한 효모 추출물을 건조시킨 분말 10 내지 90 중량%, 키토산 5 내지 80 중량%, 및 생약 재료 분말 5 내지 80 중량%를 포함하는 것을 특징으로 하는 PMS 및 월경통 완화용 조성물을 제공한다. 이 때, 상기 키토산은, 분자량 300,000 이상의 수용성 고분자 키토산인 것이 바람직하고, 상기 생약 재료는, 당귀, 단삼, 울금, 봉출, 박하, 감초, 생강, 천마, 백출, 천궁, 계피 및 인삼으로 구성되는 군으로부터 선택되는 한 가지 이상인 것이 바람직하다.It provides a composition for relieving PMS and dysmenorrhea, characterized in that it comprises 10 to 90% by weight of the dried yeast extract, 5 to 80% by weight of chitosan, and 5 to 80% by weight of the herbal material powder. In this case, the chitosan is preferably a water-soluble polymer chitosan having a molecular weight of 300,000 or more, and the herbal material is a group consisting of Angelica, Salvia, Curry, Bacteria, Mint, Licorice, Ginger, Cinnamon, Baekchul, Cheongung, Cinnamon and Ginseng It is preferably one or more selected from.
또한 상기와 같은 목적을 달성하기 위하여 본 발명은,In addition, the present invention to achieve the above object,
효모 균주를 최대증식기까지 배양하는 단계;Culturing the yeast strain to the maximum growth phase;
상기 배양된 효모를 35℃ 내지 70℃의 온도에서 자가소화시키면서, 동시에 단백질 분해 효소를 더 첨가하여 효모 단백질을 가수분해시키는 단계; 및 Hydrolyzing the cultured yeast at a temperature of 35 ° C. to 70 ° C. while simultaneously adding more proteolytic enzymes to hydrolyze the yeast protein; And
상기 가수분해된 것을 원심분리하여 상등액만을 분리하여 취하는 단계를 포함하는 PMS 및 월경통 완화 기능을 갖는 효모 추출물의 제조 방법을 제공한다. 상기 방법에서, 효모를 자가소화시키기 전에 효모가 사멸하지 않는 범위의 고온, 초음파, 진동, pH 변화 등의 적절한 물리적 또는 화학적 스트레스를 가하여 스트레스에 견디기 위한 대사물질의 분비를 유도하는 단계를 더 포함하는 것이 바람직하며, 또한 상기 수득된 상등액은 분무 건조하는 단계를 더 포함하는 것이 바람직하다. It provides a method for producing a yeast extract having a PMS and dysmenorrhea function comprising the step of centrifuging the hydrolyzed to separate only the supernatant. In the method, the method further comprises the step of inducing the secretion of metabolites to withstand stress by applying appropriate physical or chemical stresses such as high temperature, ultrasonic wave, vibration, pH change, etc. in the range that yeast does not die before self-extinguishing the yeast. Preferably, the obtained supernatant further comprises spray drying.
또한 상기와 같은 목적을 달성하기 위하여 본 발명에서는, 상기한 효모 추출물을 포함하는 것을 특징으로 하는 PMS 및 월경통 완화용 기능성 음료을 제공한다.In addition, in order to achieve the above object, the present invention provides a functional beverage for alleviating PMS and dysmenorrhea, comprising the above-mentioned yeast extract.
이하, 본 발명을 더욱 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명의 한 태양에 있어서, 월경 전기 증후군 및 월경통 완화 기능을 갖는 효모 추출물을 제공한다. In one aspect of the present invention, there is provided a yeast extract having premenstrual syndrome and dysmenorrhea function.
효모는, 상업적으로 생산되어 미생물 발효 배지, 조미료 그리고 건강보조식품의 원료로 사용되어 왔다.(Roman et al., Food Biotechnology, 6, 225, 1992) 이와 같이 효모 추출물은 건강 보조식품으로서, 영양불균형 개선, 영양 공급, 건강 증진 및 유지, 신진대사 활성 등의 용도를 갖는 것으로 알려져 있는데, (한국 건강보조식품, 특수 영양식품 협회의 식품 유형별 용도 표기 사항 참조) 그 용도가 매우 포괄적이며 광범위하게 적용되어졌을 뿐이었다.Yeast has been commercially produced and used as a raw material for microbial fermentation media, seasonings and dietary supplements (Roman et al., Food Biotechnology, 6, 225, 1992). Yeast extract is a dietary supplement and nutritional imbalance. It is known to be used for improvement, nutrition, health promotion and maintenance, metabolic activity, etc. (Refer to the indications of use by food type of Korean health supplement food and special nutrition food association). I just lost.
이에 본 발명에서는 여태까지 밝혀진 바 없는 효모추출물의 새로운 용도인, PMS 및 월경통의 완화 효과를 밝혀 내어 본 발명을 완성하게 되었다.Therefore, the present invention has been completed to the present invention by uncovering the alleviation effect of PMS and dysmenorrhea, which is a new use of yeast extract that has not been identified so far.
본 발명의 효모 추출물은 본 발명자의 먼저 출원한 특허출원 제 01-9946호에 기재한 효모추출물의 제조방법과 같은 방법으로 제조한 것을 사용한다. The yeast extract of the present invention is prepared by the same method as the production method of the yeast extract described in the applicant's first filed patent application No. 01-9946.
상기 선행 출원에서 밝힌 바와 같이, 상기와 같은 방법으로 제조한 효모 추출물은 항 스트레스 기능, 항 피로 기능 및 뇌 신경 영양인자로서의 기능을 갖는 양질의 단백질을 50%이상 함유하고 있고, 인체에 부족하기 쉬운 미네랄과 비타민이 풍부하다. 또한 상기 효모 추출물은 자가 소화 효소와 기타 단백 분해 효소로 분해되어 저분자 펩타이드 형태로 됨으로써 그 생체이용률(bioavailability)이 매우 높다. As found in the preceding application, the yeast extract prepared by the above method contains more than 50% of high-quality protein having anti-stress function, anti-fatigue function and brain neurotrophic factor, and is easy to lack in the human body. Rich in minerals and vitamins. In addition, the yeast extract is degraded by self-digesting enzymes and other proteolytic enzymes in the form of low molecular peptides, the bioavailability is very high.
본 발명에서는 상기와 같은 효모추출물에 있어서 아직까지 밝혀진 바 없는 새로운 용도인 월경 전기 증후군의 경감과 월경통의 완화 효과를 제공한다. The present invention provides a relieving effect of premenstrual syndrome and alleviation of dysmenorrhea, which is a new use that has not yet been identified in the yeast extract as described above.
본 발명의 효모 추출물이 월경 전기 증후군과 월경통의 완화에 미치는 영향은 다음과 같이 설명되어질 수 있다.The effect of the yeast extract of the present invention on the relief of premenstrual syndrome and dysmenorrhea can be explained as follows.
먼저 본 발명의 효모 추출물에 함유된 비타민과 아미노산 조성을 다음과 같이 분석하였다. First, the vitamin and amino acid composition contained in the yeast extract of the present invention were analyzed as follows.
아미노산 조성은, 본 발명의 효모 추출물 10g을 냉각 아세톤으로 탈수시킨 후 60℃ 드라이오븐에서 여과지에 펴서 건조시킨 후 경질 시험관에 시료 5 mg을 취해 6 N HCl 5 ml을 가하여 탈기한 후 밀봉하여 110℃에서 24시간 가수분해시켜서 2-3회 소량의 증류수로 씻은 다음 농축기로 50℃에서 건조시켜 염산을 제거하고 완충액을 용해하여 아미노산 자동 분석기(Deckman system 6300, USA)로 칼럼 Li 10cm No.338051 이온 교환을 사용하여 분석하였다. 그 결과를 표 1에 나타내었다.The amino acid composition is 10 g of the yeast extract of the present invention dehydrated with cold acetone and then dried on a filter paper in a 60 ° C. dry oven, followed by 5 mg of a sample in a hard test tube, 5 ml of 6 N HCl, degassed, and sealed to 110 ° C. Hydrolyzed for 24 hours, washed with a small amount of distilled water 2-3 times, dried at 50 ° C. with a concentrator to remove hydrochloric acid, and dissolved in buffer to exchange column Li 10cm No.338051 with amino acid automatic analyzer (Deckman system 6300, USA). It was analyzed using. The results are shown in Table 1.
비타민 조성은, 대한민국 식품 첨가물 공전에 수록된 미량 성분 분석법에 의거하여 분석하였고, 글 결과를 표 2에 나타내었다.Vitamin composition was analyzed based on the trace component analysis method contained in the Republic of Korea food additives, the results are shown in Table 2.
상기의 조성에서 볼수 있듯이 본 발명의 효모 추출물은 필수아미노산을 포함한 모든 아미노산이 다 들어 있으며 비타민 B군이 다량 함유되어 있고 표에는 표기되어 있지 않지만 기존의 보고에 따르면 효모에는 셀레늄, 칼슘, 크롬, 마그네슘 등 각종 미네랄이 풍부한 것이 확실한 것으로 알려져 있다.As can be seen from the above composition, the yeast extract of the present invention contains all the amino acids including essential amino acids and contains a large amount of vitamin B group and is not indicated in the table, but according to the existing reports, yeast is selenium, calcium, chromium and magnesium It is known to be rich in various minerals.
월경 전기 증후군을 가지고 있는 여성이나 월경통이 심한 여성의 경우에, 프로게스테론 결핍이나 에스트로겐/ 프로게스테론의 호르몬의 불균형, 염분과 수분의 정체, 프로스타글란딘의 결핍 또는 과잉, 프롤락틴의 과잉, 비타민 B6(피리독신) 의 결핍, 저혈당, 세로토닌 결핍등이 발견되고 있는 바, 상기와 같은 본 발명의 효모 추출물은, 각종 아미노산 및 비타민 B6를 비롯한 비타민 B군과 칼슘, 마그네슘과 같은 미네랄이 풍부히 들어 있기 때문에, 이들 성분들이 인체내에 흡수될 때 호르몬 균형과 신진대사를 신속히 활성화할 수 있다.In women with premenstrual syndrome or those with severe dysmenorrhea, progesterone deficiency or estrogen / progesterone hormone imbalance, salt and water stagnation, prostaglandin deficiency or excess, excess prolactin, and vitamin B 6 (pyridoxine) Deficiency, hypoglycemia, and serotonin deficiency have been found. As described above, the yeast extract of the present invention is rich in vitamin B group including various amino acids and vitamin B 6 and minerals such as calcium and magnesium. When absorbed into the body, it can quickly activate hormone balance and metabolism.
그런데, 월경 전기 증후군의 치료를 위한 공지의 방법, 즉, 월경 주기의 황체 형성 단계에서 프로게스테론을 투여하는 방법, 멜라토닌(N-아세틸-5-메톡시트립타민)을 투여하는 방법(대한민국 특허 제0171408호), 및 세로토닌(5-히드록시트립타민)을 투여하는 방법(대한민국 특허공개 제01-24462호) 등은 상기의 물질들을 별도로 합성하고 여기에 비타민 B6, 마그네슘등을 첨가하여 일정한 비율로 구성하여 제조하여야 하는 것이었다. 반면, 본 발명의 효모 추출물에는 상기 표 1 및 표 2에 기재된 바와 같이, 상기한 결핍되기 쉬운 호르몬 균형 조절 성분이 그 자체 내에 모두 들어있으므로 따로 물질들을 구입하여 혼합하지 않아도 되며, 효모에서 유래된 펩타이드이기 때문에 생체이용률도 뛰어나다는 유리한 점이 있다. 따라서 본 발명자들은, 효모 추출물을 주성분으로 한 여성의 월경 전기 증후군 및 월경통 완화에 유용한 건강보조식품 조성물을 발명하게 되었다.By the way, a known method for the treatment of premenstrual syndrome, that is, a method of administering progesterone in the corpus luteum formation phase of the menstrual cycle, a method of administering melatonin (N-acetyl-5-methoxytrytamine) (Korean Patent No. 0171408 No.), and a method of administering serotonin (5-hydroxytrypamine) (Korean Patent Publication No. 01-24462), etc., synthesize the above substances separately and add vitamin B 6 , magnesium, etc. It was to be constructed and manufactured. On the other hand, the yeast extract of the present invention, as shown in Table 1 and Table 2, because it contains all of the hormonal balance control components that are easy to be deficient in itself, there is no need to purchase and mix separately, peptides derived from yeast Because of this, there is an advantage that the bioavailability is also excellent. Therefore, the present inventors have invented a dietary supplement composition useful for alleviating premenstrual syndrome and dysmenorrhea in women whose yeast extract is the main ingredient.
효모 추출물이 PMS 완화 및 월경통 경감에 영향을 미치는 더욱 자세한 이유는 하기하는 바와 같다.More detailed reasons why yeast extracts affect PMS relief and menstrual pain relief are as follows.
첫째, 효모 추출물에 다량 함유된 콜린(choline)은 비타민 B 복합체로서, 아세틸 콜린을 생성하는 전구물질인데, 아세틸 콜린은 긴장 완화, 이완 등을 촉진하는 신경전달물질로서, 콜린을 다량 섭취하면 생리시 자궁 수축으로 인한 근육의 긴장을 완화시킬 수 있으며, 이로써 진통 효과를 나타낼 수 있다.First, choline (choline) contained in a large amount of yeast extract is a vitamin B complex, a precursor that produces acetylcholine. Acetylcholine is a neurotransmitter that promotes relaxation and relaxation. It can relieve muscle tension caused by contraction of the uterus, which can have an analgesic effect.
또한, 콜린에는 여러 종류의 콜린이 있는데 이 중 살리실산 콜린은 아스피린과 비슷한 진통효과가 있으므로, 월경통의 진통 효과를 나타낼 수가 있다. 월경통의 원인은 아직 정확하게 알려지지는 않았는데, 월경통이 있는 여성은 월경통이 없는 여성보다 생리시에 분비되는 프로스타글란딘 량이 많기 때문인 것으로 추측된다. 이 때, 아세틸살리실산(아스피린)이나 이브프로펜과 같은 진통제들이 바로 프로스타글란딘이 합성되는 것을 방해하여 프로스타글란딘의 분비량을 감소시키고 통증이 잘 전달 되지 않도록 함으로써 아픔을 덜 느끼게 하는 역할을 하는 것이다. In addition, choline has several types of choline, among which salicylic acid choline has an analgesic effect similar to that of aspirin, and thus may exhibit analgesic effect of menstrual pain. The cause of dysmenorrhea is not yet known correctly, presumably because women with dysmenorrhea are more prostaglandins released during menstruation than women without menstrual pain. At this time, painkillers such as acetylsalicylic acid (aspirin) or ibprofen prevent the prostaglandin from being synthesized, thereby reducing the amount of prostaglandin released and preventing pain from being delivered.
둘째, 효모추출물 조성 중 비타민 B6는 아미노산과 단백질 합성 및 대사에 매우 중요한 역할을 담당하는데, 적혈구와 항체를 만드는데 보조역할을 하고, 각종 신경전달물질을 만드는데 관여한다. 따라서 비타민 B6가 부족하면 빈혈이 되기 쉽고, 피부염과 신경장애, 경련들의 증세를 나타낼수 있기 때문에 월경 전기 증후군과 월경통의 완화에 꼭 필요한 비타민이다. 이 비타민은 생리 전기 증후군과 월경통의 완화에 효과가 있는 것으로 이미 공지되어 있는 것이다.Second, vitamin B6 in the yeast extract composition plays a very important role in the synthesis and metabolism of amino acids and proteins, plays a role in making red blood cells and antibodies, and is involved in the production of various neurotransmitters. Therefore, vitamin B6 deficiency tends to be anemia, dermatitis, neurological disorders, and convulsions because it can show the symptoms of premenstrual syndrome and dysmenorrhea is essential vitamin. This vitamin is already known to be effective in relieving premenstrual syndrome and dysmenorrhea.
세째, 효모추출물 조성 중 나이아신은 NAD(nicotinamide adenine dinucleotide)와 NADP(nicotinamide adenine dinucleotide phosphate)의 2가지의 조효소를 만드는 효소반응에 관여하는 것으로서, 세포내 미토콘드리아에서 에너지 생성을 촉진하여 뇌 세포의 기능을 촉진시키는 역할을 함으로써 정신 분열증 치료에 사용될 수 있는 것으로 알려져 있다. 따라서 PMS의 정신적 이상 증상에 효과적으로 사용될 수 있다.Third, in the composition of yeast extract, niacin is involved in the enzymatic reaction of making two coenzymes of NAD (nicotinamide adenine dinucleotide) and NADP (nicotinamide adenine dinucleotide phosphate), which promotes energy production in the mitochondria of cells and promotes the function of brain cells. It is known that it can be used to treat schizophrenia by playing a role in promoting. Therefore, it can be effectively used for mental abnormalities of PMS.
또한, 나이아신은 필수아미노산인 트립토판의 정상적인 대사산물 중 하나이고, 트립토판은 PMS 및 월경통 치료에 사용되는 것으로 알려진 세로토닌의 전구물질이므로, 트립토판과 나이아신이 다량 함유된 효모 추출물은 PMS와 월경통의 완화에 효과적이지 않을 수 없다. 즉, 세로토닌은 생체내에서 합성되는 고유 분위기-조절 진정 신경전달물질이므로, 이와 구조적으로 비슷한 나이아신이 많다는 것은 세로토닌으로 전환 가능성이 많다는 것이고 따라서 최종적으로 통증, 만성피로, 우울증을 처리하기 위한 체내 자가기작을 최대화시킨다고 말할 수 있다.In addition, since niacin is one of the normal metabolites of tryptophan, an essential amino acid, and tryptophan is a precursor of serotonin, which is known to be used for PMS and dysmenorrhea, yeast extracts containing large amounts of tryptophan and niacin are effective in relieving PMS and dysmenorrhea. Can not help That is, since serotonin is an intrinsic atmosphere-regulated sedative neurotransmitter that is synthesized in vivo, many structurally similar niacin is likely to convert to serotonin, and thus the body's own mechanisms for treating pain, chronic fatigue, and depression. Can be said to maximize.
네째, 효모추출물의 조성 중 티아민은 심장과 신경조직의 정상화에 관여하는 등 신경계에 관여하기 때문에, 혈중 티아민 수치가 떨어지는 경우에는, 우울증, 정서 불안, 수면 장애, 짜증. 행동 과잉증 등을 유발하며, 티아민을 투여하면 이러한 증상이 없어진다는 사실이 밝혀진 바 있다(뉴욕 컬럼비아 대학 러스 하렐 교수). 따라서 티아민이 풍부한 효모 추출물의 복용을 통하여, 여성들의 PMS 증상 즉 우울, 정서 불안, 수면 장애, 짜증 등을 치료하는 데 도움을 줄 수 있다.Fourth, thiamine in the composition of yeast extract is involved in the nervous system, such as in the normalization of the heart and nervous tissues, so if the blood thiamine levels are low, depression, emotional anxiety, sleep disorders, irritability. It has been shown to cause hyperactivity, and that thiamine administration eliminates these symptoms (Professor Rus Harrell, University of Columbia, New York). Therefore, by taking thiamine-rich yeast extract, it can help to treat women's PMS symptoms such as depression, emotional anxiety, sleep disorders and irritation.
다섯째, 효모추출물의 조성 중 리보플라빈은 FMN(flavin mononuc-leotide), FAD(flavin adenine dinuleotide)와 같은 조효소의 합성에 관여하며 이들 조효소는 영양소가 산화되어 에너지를 발생하는 과정이나 적혈구 및 부신피질호르몬 합성 등에 참여한다. 따라서 출혈이 있는 생리시에 꼭 필요한 영양소이다.Fifth, riboflavin is involved in the synthesis of coenzymes such as flavin mononuc-leotide (FMN) and flavin adenine dinuleotide (FAD) in the composition of yeast extract. Participate in your back. Therefore, nutrients are essential for physiological bleeding.
여섯째, 효모추출물에 많이 함유되어 있는 미네랄인 셀레늄은 항산화 효과가 비타민 E 보다도 1,900배 이상 큰 물질이다. 즉, 인체내에서 생성된 세로토닌을 비롯한 신경전달물질이 위장관이나 전달과정에서 산화되어 버리면 그 효과가 떨어지므로, 이러한 신경전달물질들이 산화되지 않도록 하는 항산화 효과가 큰 셀레늄이 존재함으로 해서, 세로토닌과 같은 신경전달물질이 효과를 최대한 발휘할 수 있도록 돕는 역할을 한다.Sixth, selenium, a mineral contained in yeast extract, is 1,900 times larger than antioxidants. In other words, if the neurotransmitters, including serotonin produced in the human body, are oxidized in the gastrointestinal tract or during the delivery process, the effect is reduced. Therefore, the presence of selenium having an antioxidant effect that prevents the neurotransmitters from oxidizing, Neurotransmitters help to get the most out of the effect.
마지막으로, 월경통시에는 칼슘과 마그네슘과 같은 미네랄이 많이 필요한데 이러한 미네랄은 식품으로써 흡수해야 생체로의 흡수가 빠르며 아미노산과 같이 먹으면 흡수가 더욱 용이해진다. 따라서 효모추출물은 미네랄과 아미노산이 둘 다 풍부하기 때문에 인체에 용이하게 흡수될 수 있어, PMS 및 생리통 완화에 유용한 효과를 나타낼 수 있다.Lastly, menstrual cramps require a lot of minerals such as calcium and magnesium. These minerals must be absorbed as foods for quick absorption into the living body. Therefore, yeast extract can be easily absorbed by the human body because it is rich in both minerals and amino acids, it can exhibit a useful effect in relieving PMS and dysmenorrhea.
상기와 같은 기전으로, 효모 추출물은 PMS 및 월경통의 완화에 매우 효과적이라는 것을 알 수 있다.By the above mechanism, it can be seen that the yeast extract is very effective for the relief of PMS and dysmenorrhea.
본 발명의 또 다른 태양에 있어서는, 상기 효모 추출물에 더하여 키토산을 포함하는 월경 전기 증후군 및 월경통의 완화 효과를 갖는 조성물을 제공한다.In still another aspect of the present invention, there is provided a composition having an alleviating effect of premenstrual syndrome and dysmenorrhea including chitosan in addition to the yeast extract.
키토산은 자가면역력을 증진시키고 칼슘의 흡수를 도우며 콜레스테롤 조절 기능을 돕는 아주 좋은 물질이다. 칼슘은 여성에게 꼭 필요한 미네랄이며 특히 월경전 증후군과 생리시 필요한 미네랄이다. 그런데 키토산이 이러한 칼슘의 흡수를 도와주기 때문에 또한 이물질 제거에 탁월하기 때문에 월경전증후군과 생리통의 완화에 유용하다. 본 발명에서 사용되는 키토산은, 분자량 300,000 이상의 수용성 고분자 키토산인 것이 바람직하다.Chitosan is a very good substance that boosts autoimmunity, helps calcium absorption and helps regulate cholesterol. Calcium is an essential mineral for women, especially premenstrual syndrome and menstruation. However, because chitosan aids in the absorption of calcium and is also excellent for removing foreign substances, it is useful for the relief of premenstrual syndrome and dysmenorrhea. The chitosan used in the present invention is preferably a water-soluble high molecular chitosan having a molecular weight of 300,000 or more.
본 발명의 또 다른 태양에 있어서는, 상기 효모 추출물 및 키토산에 더하여,당귀, 단삼, 울금, 감초, 계피, 박하, 생강, 인삼, 천마, 단삼, 천궁, 백출, 봉출 등의 생약재료를 더 포함할 수 있는, 월경 전기 증후군 및 월경통의 완화 효과를 갖는 조성물을 제공한다.In still another aspect of the present invention, in addition to the yeast extract and chitosan, herbal ingredients such as donkey, sweet ginseng, turmeric, licorice, cinnamon, peppermint, ginger, ginseng, cheonma, sweet ginseng, cheongung, baekchul, and buds may be further included. A composition having a palliative effect of premenstrual syndrome and dysmenorrhea can be provided.
당귀, 단삼, 감초, 울금, 박하, 인삼, 계피, 생강 등은 여성에게 좋은 생약원료들로서, 특히 혈액순환, 어혈제거, 통증완화, 식욕촉진 및 신진대사 기능을 돕는 것으로 알려져 있다.(본초학 참조) 월경시에는 혈액순환이 원활하지 않아 울혈이 생겨서 월경통을 겪는 경우가 많으므로, 이러한 생약성분은 그러한 월경통을 완화시킬 수 있다.Angelica, Salvia, Licorice, Turmeric, Peppermint, Ginseng, Cinnamon, Ginger, etc. are good herbal medicines for women, especially known to help blood circulation, blood removal, pain relief, appetite and metabolic functions (see herbal medicine). During menstruation, blood circulation is not smooth, so congestion occurs and often suffers from dysmenorrhea, such herbal ingredients can alleviate such dysmenorrhea.
또한 천마, 천궁, 백출, 봉출 등은 뇌의 혈액 순환을 도와주고 머리를 맑게 하므로, 신경전달물질의 생성을 도와줄 수 있다.In addition, cheonma, cheongung, baekchul, bleeding, etc. helps the blood circulation of the brain and clear the head, can help the production of neurotransmitters.
상기한 재료들은 모두 분말화하여 사용하는데, 그 배합비는, 효모추출물 10 내지 90 중량%, 키토산 5 내지 80 중량%, 및 생약재료 5 내지 80 중량%인 것이 바람직하다.The above materials are all powdered and used, and the blending ratio is preferably 10 to 90% by weight of yeast extract, 5 to 80% by weight of chitosan, and 5 to 80% by weight of herbal material.
효모 추출물을 다량 첨가할 경우 통증을 많이 느끼는 환자에게는 좋을 수 있지만, 통증이 경미한 환자에게 복용하였을 경우에는 오히려 나른하게 이완이 되는 경우가 있으므로, 그 함량을 상기 범위 내에서 적절히 조절할 필요가 있다. When a large amount of yeast extract is added, it may be good for a patient who feels a lot of pain, but when taken in a patient with mild pain, it may be rather relaxed, so the content of the yeast extract needs to be appropriately adjusted within the above range.
또 키토산을 다량 복용할 경우, 키토산이 가지고 있는 산성으로 인하여 체내에서 심한 자극으로 작용하여 몸살이 발생하는 경우가 많으므로, 정상인의 경우는 큰 무리가 없지만 월경통이 심한 환자에게는 심한 자극(긴장,스트레스)으로 작용하여 오히려 몸에 무리가 발생할 수도 있다. In addition, when a large amount of chitosan is used, the body has a lot of irritation due to the acidity of chitosan, which causes severe irritation in the body. It can act as a rather overwhelming body.
하지만 적어도 효모 추출물은 최소한 10 중량%, 키토산은 최소한 5 중량%는 포함되어야만 각각의 유효 성분을 활용하면서도 효모 추출물과 키토산의 이완과 자극의 상호 작용을 유도하여 적절한 신진 대사를 유도할 수 있다. However, at least 10% by weight yeast extract and at least 5% by weight of chitosan should be included to induce the proper metabolism by inducing the interaction of the relaxation and stimulation of the yeast extract and chitosan while utilizing each active ingredient.
또한 효모 추출물과 키토산의 최대 함유량을 각각 90 중량%와 80 중량%로 한 것도, 상기의 최소 중량비의 상호작용을 일으키는 조건과 마찬가지로 효모 추출물과 키토산의 이완과 자극의 적절한 상호 작용을 발생시켜 신진대사에 효과적인 조성물로 작용할 수 있게 하기 위해서이다. In addition, the maximum content of yeast extract and chitosan at 90% by weight and 80% by weight, respectively, is similar to the above conditions that cause the interaction of the minimum weight ratio, which causes proper interaction between relaxation and stimulation of the yeast extract and chitosan. To act as an effective composition.
아울러 생약재료의 최소 중량비를 5%로 한 것은 여성들의 생리시 완전히 제거되지 않은 어혈(뭉친 피)을 제거하는 데 도움을 주기 때문에 최소 5% 중량비의 생약 성분을 첨가시키면 바람직한 월경통 및 월경 전기 증후군 완화용 조성물을 제조할 수 있기 때문이다.In addition, the 5% minimum weight ratio of herbal ingredients helps to eliminate blood clots that have not been completely removed during menstruation, so adding herbal ingredients at least 5% weight ratio alleviates desirable dysmenorrhea and premenstrual syndrome. This is because the composition for manufacture can be prepared.
본 발명에서 제조된 PMS 및 월경통 완화용 효모추출물 및 그를 포함하는 조성물은 모두 분말화하여 캡슐에 충진하거나 정의 형태로 하여 이를 하루에 2-3회 1회에 1-2 캡슐(또는 정)씩(1 캡슐(정)은 180mg)을 다량의 물과 함께 섭취하면 여성의 월경 전기 증후군, 월경통, 냉증 및 월경불순 등의 치료에 효과적이다.PMS and dysmenorrhea yeast extract prepared in the present invention and a composition comprising the same are all powdered and filled into capsules or in the form of a definition, 1-2 capsules (or tablets) once or twice a day (2-3 times a day) 1 capsule (tablet) 180mg) with a large amount of water is effective in the treatment of women's premenstrual syndrome, dysmenorrhea, cold and dysmenorrhea.
또한 본 발명에서 제조된 효모추출물 및 그를 포함하는 조성물은 건강 음료로 제조되어 섭취됨으로써, 월경 전기 증후군, 월경통, 냉증 등의 완화에 기여하는 여성의 건강증진을 위해 이용될 수 있다.In addition, the yeast extract prepared in the present invention and the composition comprising the same can be used for health promotion of women who contribute to the relief of premenstrual syndrome, dysmenorrhea, cold symptoms and the like by being prepared as a health drink.
이하, 본 발명의 조성물의 제조 방법을 더욱 상세히 설명한다.Hereinafter, the manufacturing method of the composition of this invention is demonstrated in detail.
본 발명의 조성물의 주된 성분인 효모 추출물의 제조방법은, 35℃ 내지 70℃의 온도에서 효모를 자가소화시키고, 이것을 다시 단백질 분해효소로 가수분해시킨 것을 분리, 정제하는 과정을 포함하는데, PMS 및 월경통 완화 효과를 갖는 효모추출물을 이와 같은 방법으로 제조하는 이유는 다음과 같다.The method for preparing a yeast extract, which is a main component of the composition of the present invention, comprises the step of separating and purifying the autolyzed yeast at a temperature of 35 ° C. to 70 ° C. and hydrolyzing it again with a protease, wherein PMS and The reason why the yeast extract having a menstrual pain relief effect is prepared in this way is as follows.
즉, 효모를 자가 소화시키거나, 가수 분해 효소를 사용하여 분해시킬 때 분해 효율을 높이기 위해 가해지는 온도 자극, pH 자극 등은, 분해 효율을 높일 수 있다는 점 이외에도, 살아있는 효모에 자극, 즉 온도나 pH 등의 스트레스를 가하는 과정이라고 볼 수 있다.In other words, the temperature stimulus and pH stimulus applied to increase the decomposition efficiency when the yeast is self-digested or decomposed using a hydrolase may increase the efficiency of degradation. It can be seen that the process of applying stress, such as pH.
'모든 생체는 스트레스를 처음 지각하면 스트레스에 대항하여 신체자원을 동원하는 생리적 각성 반응이 나타나다가, 스트레스가 계속되면 유기체는 저항단계에 들어가서 스트레스를 억제하는 방향으로 생리적 변화는 진행된다'는 사실(Seyle,1956 )로 비추어 볼 때, 효모도 하나의 생체로서 외부의 자극에 대해 대응하는 반응을 나타내게 되는데, 이 때 온도나 진동, pH 등의 외부로부터 가해지는 자극에 대해 자극을 억제하는 방향으로 생리적 변화를 일으키게 된다. 그 결과 교미 페로몬과 같은 호르몬을 다량 분비하거나 미지의 항 스트레스성 물질을 분비하게 된다. 'When all living organisms perceive stress for the first time, a physiological arousal response that mobilizes body resources against stress appears, and when stress continues, the organism enters the resistance stage and proceeds to suppress the stress. In the light of Seyle, 1956), yeast also shows a corresponding response to external stimuli as a living body, in which the physiological direction in the direction of suppressing the stimulus against external stimuli such as temperature, vibration, pH, etc. Will cause a change. As a result, they secrete large amounts of hormones such as mating pheromones or secrete unknown antistress agents.
따라서 효모 추출물을 제조하는 과정에서 초음파나 진동, pH변화, 온도 변화 등을 인위적으로 가해 인체에 유익한 항 스트레스성 물질을 다량 분비하게 할 수 있다. Therefore, ultrasonic wave, vibration, pH change, temperature change, etc. may be artificially applied in the process of preparing yeast extract to release a large amount of antistress substances beneficial to the human body.
최근 인체에 침을 놓을 경우 병이 낫게 되는 원리가, 침과 같은 자극이 엔돌핀과 같은 신경 호르몬의 분비를 촉진하기 때문이라는 보고(동경의대 本剛 교수/ American Journal of Physiology June 1999)가 있고, 일반적으로 칼슘 이온 존재하에서 전기적인 자극이나, 높은 농도의 칼륨 이온으로 처리하였을 때, 시상하부의 정중 융기에서 신경 전달물질이나 신경 펩타이드의 방출이 야기된다는 사실 (신경 호르몬, 김경진, 조세형, 대우학술 총서, 2000년 p23)을 참고하여 볼 때 원시 독립 단세포 형태인 효모도 마찬가지로 고온이나 pH 변화, 초음파, 진동과 같은 각종 자극에 의해 이러한 신경 호르몬과 유사한 물질들이 분비된다고 할 수 있다.There is a recent report that acupuncture in the human body improves disease because stimulation such as saliva stimulates the release of nerve hormones such as endorphins (American Journal of Physiology June 1999). In the presence of calcium ions, treatment with electrical stimulation or high concentrations of potassium ions caused the release of neurotransmitters or neuropeptides in the medial ridge of the hypothalamus (Neurohormone, Kyung-Jin Kim, Hyung-Seop, Daewoo University, In reference to p23, 2000, yeast, a primitive independent single cell form, can be similarly secreted by neurohormones by various stimuli such as high temperature, pH change, ultrasound, and vibration.
이러한 사실을 뒷받침하는 것으로는, 포유류의 신경 펩타이드와 유사한 폴리펩타이드가 하등 척추 동물은 물론 진화 초기의 단세포 생물인 효모와 박테리아 등에서도 발견된다는 점이 있다. 특히 효모의 교미 페로몬인 α-factor는 하기하는 바와 같이 포유류의 신경 호르몬인 GnRH(성선 자극/방출 호르몬)와 구조적으로 유사하다.([신경 호르몬] 김경진, 조세형, 대우 학술 총서, 2000/ Stotzler,D.,Kiltz,H.-H&Duntz,W.(1976)Eur. J. Biochem. 69, 397-400 )Supporting this fact is that polypeptides similar to mammalian neuropeptides are found in lower vertebrates as well as in the early evolutionary single-celled organisms, yeast and bacteria. In particular, the α-factor, a mating pheromone in yeast, is structurally similar to GnRH (gonadotropin / releasing hormone), a mammalian neurohormone, as described below. [Neurohormone] Kyung-Jin Kim, Cho-Hyung, Daewoo Academic Journal, 2000 / Stotzler, D., Kiltz, H.-H & Duntz, W. (1976) Eur. J. Biochem. 69, 397-400)
α1-factor(효모)α 1 -factor (yeast)
H-Trp-His- Trp-Leu-Gln-Leu-Lys-Pro- Gly-Gln-Pro-Met-Tyr-OH H-Trp- His- Trp -Leu-Gln -Leu-Lys- Pro- Gly -Gln-Pro-Met-Tyr-OH
GnRH GnRH
PGlu-His- Trp-Ser-Tyr-Gly-Leu-Gln-Pro- Gly-NH2 (포유류) PGlu - His- Trp -Ser-Tyr- Gly-Leu-Gln- Pro- Gly -NH2 ( mammals)
PGlu-His- Trp-Ser-Tyr-Gly-Leu-Arg-Pro- Gly-NH2(닭) PGlu - His- Trp -Ser-Tyr- Gly-Leu- Arg - Pro- Gly -NH2 ( chicken)
PGlu-His- Trp-Ser-Tyr-Gly-Leu-Ser-Pro- Gly-NH2 (감성돔) PGlu - His- Trp -Ser-Tyr- Gly-Leu-Ser- Pro- Gly -NH2 ( black sea bream)
더군다나 생 효모가 생장하는 액상 배지 상태에서 가해지는 자극은 다세포 생물에 비해 단세포 생물들이 자극을 받는 표면적이 매우 크므로 액상 배지 상태에서 가해지는 자극은, 단세포가 모여서 다세포로 진화된 생물체에 비해 매우 효과적이라고 할 수 있다. Furthermore, the stimulus applied in the liquid medium in which the live yeast grows is much more effective than the multicellular organisms, so the stimulus in the liquid medium is more effective than the single cells that have evolved into multicellular organisms. It can be said.
따라서 이러한 자극을 가하는 공정을 추가할 경우 더욱 기능이 뛰어난 효모 추출물을 생성할 수 있다. Therefore, the addition of this stimulating process can produce a more functional yeast extract.
뿐만 아니라 소화관에서 검출되었던 많은 펩타이드가 뇌 조직에서도 발견되고, 또 신경조직에만 분포한다고만 알려진 신경호르몬과 신경 펩타이드가 소화관과 피부 등 여러 비 신경조직인 내분비계에서 발견되고 있어, 이는 진화학적인 관점에서 볼 때 신경전달물질, 신경 펩타이드 그리고 호르몬이 모두 원시적인 단세포 생물에 존재하던 하나의 세포 조절인자에서 유래된 것임을 시사한다. (신경 호르몬, 김경진, 조세형, 대우학술 총서, 2000년 p20 )In addition, many peptides detected in the digestive tract are found in the brain tissue, and neurohormones and peptides known to be distributed only in the nervous tissue are found in the endocrine system, which is a non-neural tissue such as the digestive tract and skin. It suggests that neurotransmitters, neuropeptides and hormones are all derived from one cell regulator that was present in primitive unicellular organisms. (Neurohormone, Kyung-Jin Kim, Se-Hyung Jo, Daewoo Medical Research, 2000 p20)
따라서 원시 단세포 생물인 효모에 대한 자극으로 인해 분비된 각종 분비 물질(exoenzyme)이 함유되어 있는 본 발명의 효모 추출물이, 신경전달물질로서 작용함으로써 인체의 PMS나 월경통 등의 통증 완화에도 유효하게 작용을 할 수 있다. Therefore, the yeast extract of the present invention, which contains various secretory substances (exoenzyme) secreted due to the stimulation to the yeast, a primitive unicellular organism, acts as a neurotransmitter to effectively relieve pain such as PMS or dysmenorrhea in the human body. can do.
실시예Example
이하 실시예를 들어 본 발명을 더욱 구체적으로 설명하나, 실시예는 본 발명을 한정하는 것으로 해석해서는 안되며, 본 발명의 범위내에서 당업자의 통상적인 변화가 가능하다. Although the present invention will be described in more detail with reference to the following examples, the examples should not be construed as limiting the present invention, and conventional variations of those skilled in the art are possible within the scope of the present invention.
실시예Example 1 One
식품등급의 효모균인 Saccharomyces cerevisiae 균주(제니코(주) 생이스트를 구입하여 사용)를 YM 배지에서 24℃, 산소공급하에서 48시간 배양하였다. Food grade yeast Saccharomyces cerevisiae strain (purchased by Genico Co., Ltd.) was incubated in YM medium at 24 ° C. and oxygen for 48 hours.
상기와 같이 배양된 배양액을 15,000rpm으로 15분간 원심분리하여 상등액을 제거하고 남은 침전물, 즉 효모를 10배(v/v)멸균수로 2회 세척, 희석한 후, 50℃의 고온에서 효모가 자신을 용해시키는 자가소화(autolysis) 효소를 이용하여 자가소화를 실시함과 동시에, 효모 단백질을 펩타이드로 분해하는 것을 촉진시키기 위해 단백질 분해효소(파파인 30.000)를 1%를 첨가하여 초기 pH 4.0에서 48시간 가수분해를 수행하여 단백질을 펩타이드로 용해하였다. After centrifuging the culture broth as described above for 15 minutes at 15,000 rpm, the supernatant was removed, and the remaining precipitate, ie, the yeast was washed and diluted twice with 10 times (v / v) sterilized water, and then the yeast was heated at a high temperature of 50 ° C. In addition to self-digestion using an autolysis enzyme that dissolves itself, 1% of protease (papaine 30.000) was added to facilitate the breakdown of yeast proteins into peptides. Time hydrolysis was performed to dissolve the protein into peptides.
이와 같이 용해된 것을 15,000 rpm에서 원심분리하여 수용액 상태인 상등액만을 분리하여 분무 건조하였다. The dissolved solution was centrifuged at 15,000 rpm to separate only the supernatant in an aqueous solution and spray dried.
또한 당귀, 단삼, 울금, 봉출, 박하, 및 인삼을 각각 동일 무게의 비율로 분말화 한 다음 잘 섞어 생약 재료를 준비하였다.In addition, powdered Angelica, Salvia, Turmeric, Bulgogi, Mint, and Ginseng at the same weight ratio, respectively, and then mixed well to prepare a herbal medicine material.
또한 키토산은 분자량 30만 이상인 수용성 고분자 키토산((주)자광 키토산으로부터 구입)을 준비하였다.In addition, chitosan prepared the water-soluble high molecular chitosan (purchased from the light magnetic chitosan Co., Ltd.) whose molecular weight is 300,000 or more.
상기와 같이 준비된 재료를, 효모 추출물 40 중량% , 키토산 30 중량%, 생약 재료 30 중량%의 비율로 혼합한 후, 캡슐에 충진하여 180mg을 1 캡슐로 하였다. The ingredients prepared as above were mixed at a ratio of 40% by weight of yeast extract, 30% by weight of chitosan, and 30% by weight of herbal medicine, and then filled into capsules to make 180 mg of 1 capsule.
실시예Example 2 2
생명공학연구소(KCTC)에서 분양받은 식품등급의 Saccharomyces cerevisiae 7904 균주를 YM 배지에서 24℃, 산소공급하에의 발효조에서 48시간 배양하였고, 그 배양액을 5,000rpm으로 15분간 원심분리하여 상등액을 제거하고 남은 침전물인 효모 페이스트(paste)를 1% 펩톤 완충액으로 10배 희석한 후 초음파 발생장치와 진동장치가 부착된 발효조에서 35℃ 내지 45℃의 고온과 45Khz의 초음파를 5분 간격으로 30초간 가하는 행위를 총 8시간 동안 반복하고, 수중 펌프를 이용하여 낙차를 이용한 진동을 주면서 효모가 스트레스로 인해 분비하는 항 스트레스 물질의 생성이 많이 발생되게 하면서 8시간 배양하였다.Food-grade Saccharomyces from KCTC The cerevisiae 7904 strain was incubated for 48 hours in a fermenter at 24 ° C. and oxygen supply in YM medium. The culture solution was centrifuged at 5,000 rpm for 15 minutes to remove the supernatant, and the remaining precipitate, yeast paste, was treated with 1% peptone buffer. After diluting 10 times, in the fermentation tank equipped with the ultrasonic generator and the vibrator, the high temperature of 35 ℃ to 45 ℃ and the ultrasonic wave of 45Khz for 30 seconds are repeated for 5 seconds and the drop by using the water pump While giving a vibration using the yeast is incubated for 8 hours while generating a lot of production of anti-stress substances secreted by the stress.
상기의 배양된 배양액을 50℃의 고온에서 효모가 자신을 용해시키는 자가소화 효소를 이용하여 자가소화를 실시하였다. 이와 함께 효모 단백질의 가수분해를 촉진시키기 위해 단백질 분해효소(파파인 30.000) 1%를 첨가하고 초기 pH 4.0에서 48시간 가수분해를 수행하여 단백질을 저분자 펩타이드로 용해하였다.The cultured culture was subjected to self-extinguishing using a self-extinguishing enzyme in which yeast dissolves itself at a high temperature of 50 ° C. In addition, 1% protease (papaine 30.000) was added to promote the hydrolysis of the yeast protein, and the protein was dissolved in a low molecular peptide by 48 hours of hydrolysis at an initial pH of 4.0.
상기에서와 같이 자가소화 및 가수분해된 것을 15,000 rpm에서 원심분리하여 수용액 상태인 상등액만을 분리하여 분무 건조하여 효모 추출물을 제조하였다. As described above, the autodigested and hydrolyzed was centrifuged at 15,000 rpm to separate only the supernatant in aqueous solution and spray dried to prepare a yeast extract.
당귀, 단삼, 울금, 봉출, 박하, 감초, 생강, 천마, 백출, 천궁 및 인삼을 각각 동일 무게의 비율로 분말화 한 다음 잘 섞어 생약 재료를 준비하였다.Powdered Angelica, Sweet Ginseng, Turmeric, Bulgogi, Mint, Licorice, Ginger, Cheonma, Baekchul, Cheongung, and Ginseng were each powdered in the same weight ratio, and then mixed well to prepare herbal ingredients.
또한 키토산은 실시예 1에서와 같은 종류의 키토산으로 준비하였다.In addition, chitosan was prepared with the same kind of chitosan as in Example 1.
상기와 같이 준비된 재료를, 효모 추출물 70 중량% , 키토산 10 중량%, 생약 재료 20 중량%의 비율로 혼합한 후, 캡슐에 충진하여 180mg을 1 캡슐로 하였다. The ingredients prepared as above were mixed at a ratio of 70% by weight of yeast extract, 10% by weight of chitosan, and 20% by weight of herbal medicine, and then filled into capsules to make 180 mg of 1 capsule.
실험예 1(황 원준 신경 정신과 전문의 임상실험) Experimental Example 1 (Clinical Experiment by Hwang Won-Joon Neuropsychiatrist)
실시예 1에 의해 제조된 캡슐을 20-35세 여성 30명에게 특히, 월경전기증후군, 월경통, 냉증 등이 있는 여성들에게 월경 전, 또는 월경통이 있는 월경중에 1회 1-2캡슐씩, 1일 2-3회 섭취하도록 하였다. The capsules prepared according to Example 1 were given to 30 women aged 20-35 years, 1 to 2 capsules once a day before menstruation or during menstruation with menstruation, especially for women with premenstrual syndrome, dysmenorrhea and coldness. It was taken 2-3 times.
그 적용한 결과로써 나타나는 여러가지 변화에 대하여 설문 조사를 하였다. 이 때 총 변화 평가표의 문항은 30문항으로 선택하였으며, 각각 신체적 증상 10문항, 정서적 증상 10문항, 행동적 증상 10문항으로 구성하였다. 30개의 조사 문항은 다음과 같았다.The survey was conducted on various changes resulting from the application. At this time, 30 items of total change evaluation table were selected and 10 items of physical symptoms, 10 items of emotional symptoms, and 10 items of behavioral symptoms were composed. The 30 survey questions were as follows.
A) 신체 증상 (somatic symptoms)A) somatic symptoms
1)힘이 없거나 피로감을 느낀다.1) Feeling weak or tired
2)식욕이 증가하거나 감소한다.2) appetite increases or decreases.
3)유방이 붓거나 아프다. 3) The breast is swollen or sick.
4)머리가 아프다.4) Head hurts
5)매스껍거나 토한다.5) Masquerade or vomit.
6)어지럽거나 현기증이 난다.6) dizzy or dizzy.
7)몸이 붓는다.7) Your body is swollen.
8)배가 아프거나 불편하고 간헐적인 복부 경련이 있다.8) The stomach is sore or uncomfortable and there are intermittent abdominal cramps.
9)불면증이 있다.9) I have insomnia.
10)성적인 활동이나 흥미가 변한다.10) Sexual activity or interests change.
B) 정서 증상 (emotional symptoms)B) emotional symptoms
1)하루 내에 여러 감정들의 빠른 변화가 있다.1) There is a rapid change of emotions in one day.
2)마음이 불안하고 안절부절 못한다.2) The mind is uneasy and restless.
3)신경이 예민해지거나 침착하지 못하다.3) The nerves become sensitive or calm.
4)슬프거나 우울하다.4) Sad or depressed
5)하찮은 문제에 대해 잔소리를 하거나 언쟁을 벌인다.5) Nagging or arguing about trivial matters.
6)속이 상하면 히스테리칼해 진다.6) If the stomach is damaged, it becomes hysterical.
7)죄책감을 느낀다.7) I feel guilty.
8)다른 사람들의 결점이나 실수에 대한 이해심이 적다.(또는 참을성이 없다)8) Less understanding of others' faults or mistakes (or impatient)
9)불쾌한 사건에 대해 곰곰히 생각하거나 걱정한다.9) Think about or worry about unpleasant events.
10)무뚝뚝해진다.10) Blunt
C) 행동 증상 (behavioral symptoms) C) behavioral symptoms
1)움직임이 둔해지거나 서투르다. 1) The movement becomes dull or clumsy.
2)실수나 사고를 저지른다.(떨어지거나 칼에 베이거나 우연히 물건을 파손)2) Make mistakes or accidents (falls, cuts or accidental damage)
3)죽음이나 자살에 대해 생각한다.(또는 잠들어서 영원히 깨어나고 싶지 않다)3) Think about death or suicide (or don't want to fall asleep and wake up forever)
4)말하기가 싫거나 돌아다니기 싫다.4) I don't want to talk or wander around.
5)약물남용(각성제, 진정제 등)을 한다.(또는 담배나 술을 많이 한다.)5) Use drug abuse (stimulants, sedatives, etc.) (or smoke or smoke a lot).
6)난폭해지거나 짖굿게 행동한다.6) Be violent or barking.
7)가정이나 직장에서의 능력이나 활동, 사회적인 참여가 감소한다.7) Reduces ability, activity, and social participation in the home or workplace.
8)사회활동을 피하고 집안에만 혼자 있기를 원한다.8) Avoid social activities and want to be alone in the house.
9)가사일(청소, 빨래 등)을 덜한다.9) Reduce household chores (cleaning, laundry, etc.).
10)여가활동(취미생활, TV시청, 독서 등)으로 보내는 시간이 적다.10) Less time spent on leisure activities (hobbies, watching TV, reading, etc.).
상기의 문항에 대하여, 변화가 심한 정도에 따라서 증상이 전혀 없는 것은 1, 거의 없는 것은 2, 약간 있는 것은 3, 상당히 있는 것은 4, 꽤 심한 것은 5, 아주 심한 것을 6으로 답변하도록 하였으며, 전체적인 느낌을 섭취 전과 후로 나누어서 조사하고, 통증완화 효과가 나타나는 시간과 지속시간 등을 조사하였다. 이렇게 개인 별로 조사한 수치를 모두 합하여 평균을 낸 평균 수치를 산출해 보았다.For the above questions, depending on the severity of the change, there were 1 symptom with no symptom, 2 with little symptom, 3 with some symptom, 4 with very severe, 5 with very severe, and 6 with very severe. Was divided into before and after ingestion, and the time and duration of pain relief effect were investigated. In this way, the total number of individual surveys was added to calculate the average.
그 결과 섭취 후 빠르게는 10분안에 적어도 1시간안에는 진통 완화의 효과가 나타났으며, 그 지속시간이 약 4-6시간 정도로 나타났으며 그 변화의 정도는 신체, 정서, 행동의 모든 영역에서 월경으로 인한 증상이 개선된 것으로 나타났다. As a result, pain relief was effective within 10 minutes after ingestion at least 1 hour, and the duration was about 4-6 hours, and the degree of change was menstruation in all areas of body, emotion and behavior. It has been shown that the symptoms due to the improvement.
그 평균적인 변화 정도는 아래의 표와 같다.The average degree of change is shown in the table below.
실험예Experimental Example 2 2
본 발명 조성물에 대한 생리시의 통증 완화 효과 및 기타 효과를 확인하기 위해 20세에서 35세 사이의 가임 여성에게, 설문의 예를 들지 않고, 복용 전 증상, 복용 후 효과가 나타날 때까지의 시간, 복용 후의 효과, 복용 후 효과의 지속시간에 대해 그 효과를 직접 기술하도록 하였다. For women of childbearing age between 20 and 35 years of age to confirm the pain relief and other effects during menstruation for the composition of the present invention, without taking an example of a questionnaire, symptoms before taking, time to take after taking, Post-dose effects and duration of post-dose effects were described directly.
복용시기는 통증이 오는 시점에 실시예 1의 조성물이 담긴 180mg (1캡슐)을 1일 1-2정씩 복용하도록 하였다. Dosing time was 180 mg (1 capsule) containing the composition of Example 1 at the time of pain comes to take 1-2 tablets daily.
설문에 응해준 여성들의 의견은 다음과 같았다.The opinions of the women who responded to the survey were as follows.
1. 29세의 한 직장 여성의 경우, 본 발명의 조성물을 복용하기 전의 월경시 증상으로는 아랫배가 아프고 소화가 잘 되지 않으며 식은 땀이 나고 혈액 순환이 잘 되지 않고 손발이 저렸다고 했다. 하지만 복용 후 약 20-25분 후 편안하게 잠들 수 있었고 잠에서 깬 후 개운하였다고 한다. 일반 진통제를 복용할 경우는 복용 후 얼굴이 붓고 속이 좋지 않았으나 본 발명 조성물이 담긴 캡슐 복용시에는 통증이 없어지면서도 그러한 부작용이 없었다.1. A 29-year-old female worker reported that the symptoms of menstruation before taking the composition of the present invention were pain in the lower abdomen, indigestion, cold sweating, poor circulation, and limbs. However, about 20-25 minutes after taking it, she could sleep comfortably and wake up after waking up. When taking general pain medication, the face was swollen after taking it, and the stomach was not good, but when taking the capsule containing the composition of the present invention, the pain was eliminated, but there was no such side effect.
2. 32세의 미혼 직장 여성의 경우, 월경시, 본 발명의 조성물을 복용하기 전에는 허리통증이 심하고 아랫배에 불쾌감이 있었으나, 본 발명의 조성물의 캡슐 2정을 복용한 후 약 30분 후에 통증이 완화되는 것을 느낄 수 있었다. 2. A 32-year-old unmarried female worker had a severe back pain and discomfort in her lower stomach before taking the composition of the present invention at menstruation, but after about 30 minutes after taking two capsules of the composition of the present invention I could feel relief.
3. 30세의 연구직 종사 미혼 여성의 경우, 월경 하루 전부터 소화가 잘 안되고 배가 불룩 튀어나오면서, 월경 시작과 함께 계속 설사를 하고 아랫배와 허리의 통증이 심하였다고 한다. 또한 배가 차가와지고 기분이 우울해지기도 하고 예민하여 짜증도 잘 내었다. 하지만 복용후 약 30분 후부터 일단 아랫배의 통증의 가라앉으면서 몸이 편해지고 배가 차가왔던 것도 나아지는 것 같았고 짜증도 덜 났다고 한다. 복용 후 이러한 효과가 4-5시간 이상 길게는 반나절 정도 지속되었으며 설사도 나지 않았다.3. A 30-year-old unemployed female researcher reported that she had difficulty digesting and bulging her abdomen a day before menstruation, and continued diarrhea at the beginning of menstruation. In addition, my stomach became cold and depressed and sensitive and irritable. However, about 30 minutes after taking it, the pain in the lower abdomen has subsided, the body feels better and the stomach feels better and less irritable. This effect lasted for about half a day for more than 4-5 hours and did not have diarrhea.
4. 방송작가인 33세의 기혼 여성의 경우 월경 첫날은 전혀 활동할 수 없을 만큼 월경통이 심했다. 월경 시작일 하루 전 본 캡슐을 2알 씩 2회 총 4알을 복용한 후부터 월경 중에도 활동이 가능할 정도로 통증이 완화되었으며 움직이는 데 불편이 없었다. 이러한 효과가 이틀간 지속되었다. 4. A 33-year-old married woman who was a broadcast writer had severe dysmenorrhea so that her first day of menstruation was inactive. After taking 4 capsules of 2 capsules 2 times a day before the start of menstruation, the pain was relieved enough to be active during menstruation and there was no discomfort. This effect lasted for two days.
5. 32세의 한 직장여성의 월경시 증상은 진통제를 복용해야 할 정도로 심하지는 않지만 배가 사르르 아파 기분이 나빠지며 배도 더부룩하고 식욕이 감소했다. 본 캡슐 복용 후 약 40분 후부터 통증이 없어졌으며 배가 아프던 것도 없어져서 상쾌해지면서 기분이 나아짐을 경험하였다. 5. The menstrual symptom of a 32-year-old female worker is not as bad as pain medication, but her stomach hurts and her stomach feels bloated and her appetite decreases. About 40 minutes after taking this capsule, the pain disappeared and my stomach aches and pains disappeared and I felt refreshed and feeling better.
6. 32세의 공무원인 한 여성은, 월경시 손발이 저리고 어지러웠으며, 멀미처럼 울렁거릴 때가 많았는데, 본 캡슐 복용 후 40분 정도 후부터 이러한 증상이 완화되었으며, 식욕이 증진되었다고 한다. 복용 후 효과는 4-5시간 정도 지속되는 것 같았고, 빈혈도 와화됨을 느꼈다.6. A 32-year-old official said she had dizziness, dizziness, and dizziness in her menstruation during menstruation, and her symptoms were alleviated about 40 minutes after taking this capsule. The effect seemed to last about 4-5 hours, and the anemia felt to be aging.
7. 28세의 번역일을 하는 한 미혼 여성은 월경통이 심하지는 않으나, 월경 시작 전에 기분이 우울해지면서 짜증도 늘어나고 예민해진다고 한다. 그러나 본 캡슐 복용 후 40-50분 후부터 약간의 생리통이 없어졌고, 더부룩하던 배가 편안해졌으며, 예민한 성격도 나아짐을 느꼈다. 복용 후 효과가 지속되는 시간은 3-4시간 가량 되었다.7. A 28-year-old unmarried woman who is on a translation day does not have severe menstrual pain, but she feels depressed before she starts menstruation, causing her to become irritable and sensitive. But after 40-50 minutes after taking this capsule, some menstrual cramps disappeared, my bloated stomach became more comfortable, and I felt better. The duration of effect after taking it was about 3-4 hours.
8. 32세의 인테리어 디자이너인 한 직장 여성은 생리통이 매우 심하여 항상 진통제를 먹여야 했고 생리혈도 적었으며 손발이 차고 저렸다. 하지만 본 캡슐 복용후 20-30분 정도 지나면서부터 통증이 많이 없어졌고 그 느낌이 부드러웠으며 생리혈도 많아졌고 출혈시의 통증이 없어졌다. 복용 후 2-3시간 후 부터 효과가 나타나기 시작했으며 배가 따뜻해짐을 느끼고 기분도 좋아져서 짜증이 안났다. 8. A 32-year-old interior designer had a severe menstrual cramp so she always had to take painkillers, low menstrual blood, and cold hands and feet. But after 20-30 minutes after taking this capsule, the pain disappeared, the feeling was soft, the menstrual blood increased, and the bleeding pain disappeared. The effect began to appear 2-3 hours after taking it, and my stomach felt warmer and feeling better.
9. 23세의 한 대학생의 경우 생리통이 심해서 생리 시작 전 진통제를 먹어야 했으며 배가 차가워졌다. 하지만 본 캡슐 복용 후 15분에서 20분 경과 후부터 곧바로 배가 따뜻해지며 생리통이 거의 없어졌으며 활동하기에 좋았다. 효과가 지속되는 시간은 2-3시간 정도였다. 9. A 23-year-old college student had severe menstrual pain and had to take painkillers before starting menstruation and became cold. But after 15 to 20 minutes after taking this capsule, my stomach became warm and almost no menstrual pain. Duration of effect lasted 2-3 hours.
10. 23세의 연구직 종사 여성의 경우 평소 생리통이 심하지는 않았으나 신경이 예민해져서 짜증을 자주 내었다. 본 캡슐 복용 후 20-30분 후부터 신경이 다소 안정됨을 느끼고 그 효과가 약 5-6시간 지속되는 것 같았다. 10. A 23-year-old female researcher did not usually have severe dysmenorrhea, but she was often irritated by nervousness. 20-30 minutes after taking this capsule, the nerves felt somewhat stable and the effect seemed to last about 5-6 hours.
11. 38세의 한 주부는 평소 생리통이 너무 심하여 자궁 제거 수술을 결심할 정도로 통증이 심하였는데 본 캡슐을 약 1주일 복용 후부터 통증을 참을 수 있을 정도로 완화되어서 수술을 하지 않기로 했다. 11. A 38-year-old housewife suffered from severe menstrual cramps and was so painful that she decided to remove the uterus. After taking this capsule for about a week, she decided not to operate.
12. 28세의 교사인 한 여성은 평소 생리시 2-4알 씩 진통제를 복용할 정도로 심하였으나 본 캡슐 복용 후 통증이 없어졌고 그 효과가 4-5시간 지속되었다.12. A 28-year-old teacher was severe enough to take 2-4 tablets of normal menstruation during her menstruation, but her pain was gone after taking this capsule and the effect lasted 4-5 hours.
설문에 응해준 여성들의 개인적인 의견을 쓴 것을 종합해 본 결과 다음과 같았다. The results of writing the personal opinions of the women who responded to the survey were as follows.
즉, 본 발명 조성물은 월경 전, 또는 월경 중, 통증이 심하고 몸에 마비가 오기도 하고 음식을 소화시키지 못하고 토하는 증상에도 효과적으로 작용하여 호전시키는 것으로 나타났으며 혈액 순환이 좋아지고 기분도 좋아지게 하는 것으로 나타났다. 본 발명 조성물을 섭취한 여성의 대부분은 섭취 전에는 비관적이고 우울했던 기분이 섭취 후에는 없어졌다고 말했다. 본 발명 조성물은 특히 월경시의 요통에도 효과적인 것으로 나타났는데 복용 후 평가 설문에 참여한 여성 중 월경시 유달리 요통으로 심한 고생을 하던 여성이 본 발명 조성물을 한번에 2캡슐(180mg/캡슐)을 섭취한 후 30분만에 요통이 사라져 그 이후에도 꼭 섭취했으면 좋겠다고 말했다. 또한 본 발명 조성물은 생리통으로 인해서 잠을 깊게 자지 못하고, 생리통으로 잠에서 여러번 깨었던 여성들이 섭취 후 편안한 잠을 잘 수 있었다고 한다. 더 나아가, 본 발명 조성물은 기존의 진통제처럼 감각이 마비되어 무감각해지면서 진통효과가 나는 것이 아니고, 약간의 진통은 남아 있지만 기분이 나쁘지 않을 정도이므로 오히려 감각이 없어져서 진통 효과가 나는 것보다는 더 좋다는 의견이 대부분이었다. 또한 본 발명 조성물은 생리 시 손발이 차가워지고, 복부가 차가워지는 것을 완화시켜 이를 섭취한 여성의 대부분은 복부와 손발이 따뜻해졌다고 말했다. 특히 본 발명의 조성물은 월경 시작 전에 복용한 여성들에게서 더 큰 효과가 나타났으며, 통증이 시작한 다음 복용한 경우는 평균 3-4시간 지나고 나서부터 효과가 나타났다. 또한 설문에 응한 여성들의 의견 중에는, 진통제가 좋지 않다는 생각으로 그냥 통증을 참고 있었는데 본 발명의 조성물은 건강증진 효과와 함께 통증완화 효과가 있어서 기존의 진통제 의약품 대신 앞으로는 식품인 본 발명 조성물을 섭취하겠다는 반응을 나타내었다.In other words, the composition of the present invention before or during menstruation, the pain is severe, the body is paralyzed, the food is not digested and appeared to work effectively to improve the symptoms of vomiting, improve blood circulation and improve mood appear. Most of the women who took the composition of the present invention said that the pessimistic and depressed mood before ingestion disappeared after ingestion. The composition of the present invention has been shown to be particularly effective for menstrual low back pain. Among women who participated in the post-dose evaluation questionnaire, women who suffered severely from menstrual low back pain after taking 2 capsules (180 mg / capsule) of the present invention at a time 30 Low back pain disappeared in a minute, he said, I hope you will eat again. In addition, the composition of the present invention can not sleep deeply due to menstrual cramps, and women who have woken up several times from menstrual cramps were able to sleep comfortably after ingestion. Furthermore, the composition of the present invention does not have an analgesic effect as numbness and numbness as a conventional analgesic, and some analgesic remains but not feeling bad, so rather than feeling lost, it is better than the analgesic effect. This was mostly. In addition, the composition of the present invention said that during menstruation, the hands and feet became cold and the abdomen became cold, and most women who consumed said that the abdomen and hands and feet were warmed. In particular, the composition of the present invention showed a greater effect in women who took before the start of menstruation, and when taken after the onset of pain, the effect appeared after an average of 3-4 hours. In addition, among the opinions of the women who answered the question, the pain relief agent is not good, but I just referred to the pain, but the composition of the present invention has a pain-relieving effect along with the health promoting effect, so that instead of the conventional analgesic medicine, the reaction to take the present invention composition is a food. Indicated.
실험예Experimental Example 3 3
질환의 정도에 따라 차이는 있지만 여성 중 건강이 좋지 않은 5명에게 10일 내지 50일 정도 장기 섭취하게 한 결과, 월경 전기 증후군, 월경불순, 월경통, 요통, 냉증 등의 완화 효과가 우수하였고, 체력이 약했던 여성이 건강해져서 생활에 활력을 찾는 등 여성의 건강증진에도 효과적임을 알 수 있었다.Although there were differences according to the degree of disease, five women who were in poor health were given long-term intakes for 10 to 50 days, resulting in excellent relieving effects such as premenstrual syndrome, dysmenorrhea, dysmenorrhea, low back pain, and cold symptoms. This weak woman was found to be effective in promoting women's health, such as finding health and vitality in life.
효모 추출물의 이러한 새로운 용도는, PMS나 월경통에 있어서 의사나 약사의 처방으로 투여되던 의약품이나 세로토닌, 멜라토닌과 같은 특정 제품 대신, 내성이나 부작용이 없고 안전성이 보장된 식품으로서의 효모 추출물을 의사나 약사의 처방없이 간편하게 구입, 섭취할 수 있게 함으로써, 환자라고 하기에는 곤란한 정상적인 여성들이 매달 겪는 PMS나 월경통으로 인하여 겪는 고통을 쉽게 경감시킬 수 있게 한다. This new use of yeast extract replaces drugs that have been prescribed by doctors or pharmacists in PMS or dysmenorrhea, or certain products such as serotonin and melatonin, which replace yeast extracts as foods that have no resistance or side effects and are guaranteed to be safe. By making it easy to buy and consume without prescription, it is easy to relieve the pain caused by monthly PMS or dysmenorrhea among normal women who are difficult to call a patient.
도 1은 본 발명의 효모 추출물 및 이를 포함하는 조성물의 제조방법을 개략적으로 도시한 흐름도이다.1 is a flow chart schematically showing a yeast extract of the present invention and a method for producing a composition comprising the same.
Claims (11)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0026208A KR100487887B1 (en) | 2001-05-14 | 2001-05-14 | East extract relaxing premenstrual sydrome and menstrual pain, compositions containing the same, and preparation thereof |
US10/469,271 US20040101934A1 (en) | 2001-02-27 | 2002-02-27 | Peptide derived from yeast having activities as anti-tsress, anti-fatigue and brain neurotrophic factor and relaxing premenstrual syndrome and menstrual pain, and preparing process thereof |
JP2002567325A JP3930808B2 (en) | 2001-02-27 | 2002-02-27 | Yeast-derived functional peptide having anti-stress function, anti-fatigue function, premenstrual syndrome and menstrual pain alleviating function and function as neurotrophic factor and method for producing the same |
PCT/KR2002/000324 WO2002067959A1 (en) | 2001-02-27 | 2002-02-27 | Peptide derived from yeast having activities as anti-tsress, anti-fatigue and brain neurotrophic factor and relaxing premenstrual syndrome and menstrual pain, and prepairing process thereof |
US11/141,497 US7473426B2 (en) | 2001-02-27 | 2005-05-31 | Method for selectively inhibiting reuptake of serotonin and norepinephrine using yeast extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0026208A KR100487887B1 (en) | 2001-05-14 | 2001-05-14 | East extract relaxing premenstrual sydrome and menstrual pain, compositions containing the same, and preparation thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020087572A KR20020087572A (en) | 2002-11-23 |
KR100487887B1 true KR100487887B1 (en) | 2005-05-06 |
Family
ID=27704813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2001-0026208A KR100487887B1 (en) | 2001-02-27 | 2001-05-14 | East extract relaxing premenstrual sydrome and menstrual pain, compositions containing the same, and preparation thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100487887B1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100989174B1 (en) | 2010-02-01 | 2010-10-20 | (주)새롬바이오 | Yeast hydrolysate having improved effect on female climacteric disorder and a food composition comprising thereof |
KR101168225B1 (en) | 2012-03-12 | 2012-07-30 | (주) 씨엔텍 | Fermented extract of mixed biodrugs and vagina cleaning composition for woman containing the extract |
KR101497226B1 (en) * | 2013-07-31 | 2015-02-27 | 고결 | Method for making products containing korean composition material |
KR102375604B1 (en) | 2020-12-11 | 2022-03-16 | 이예진 | Composition of health suppliment food for relieving menstrual pain and health suppliment food using the same |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100912912B1 (en) * | 2007-03-30 | 2009-08-20 | 강홍구 | Herbal composition for relieving and treating primary dysmenorrhea |
US20150157679A1 (en) * | 2012-07-30 | 2015-06-11 | Pt. Soho Industri Pharmasi | Herbal formulation for treating a menstrual-related condition |
CN109247447B (en) * | 2017-07-12 | 2022-03-08 | 安琪酵母股份有限公司 | Yeast hydrolysate for replacing plasma protein powder to produce milk replacer and preparation method thereof |
-
2001
- 2001-05-14 KR KR10-2001-0026208A patent/KR100487887B1/en not_active IP Right Cessation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100989174B1 (en) | 2010-02-01 | 2010-10-20 | (주)새롬바이오 | Yeast hydrolysate having improved effect on female climacteric disorder and a food composition comprising thereof |
KR101168225B1 (en) | 2012-03-12 | 2012-07-30 | (주) 씨엔텍 | Fermented extract of mixed biodrugs and vagina cleaning composition for woman containing the extract |
KR101497226B1 (en) * | 2013-07-31 | 2015-02-27 | 고결 | Method for making products containing korean composition material |
KR102375604B1 (en) | 2020-12-11 | 2022-03-16 | 이예진 | Composition of health suppliment food for relieving menstrual pain and health suppliment food using the same |
Also Published As
Publication number | Publication date |
---|---|
KR20020087572A (en) | 2002-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2124972B1 (en) | Use of a composition made of mineral nutrients and optionally acetogenic and/or butyrogenic bacteria in order to avoid or reduce the formation of gas in the large intestine of a mammal and the resulting abdominal problems | |
TWI583390B (en) | Ellagitannins rich extracts composition | |
KR101132392B1 (en) | Fermented Placenta Compositin and Use Thereof | |
JP2004521919A (en) | Yeast-derived functional peptide having anti-stress function, anti-fatigue function, premenstrual syndrome and menstrual pain relieving function, and function as cranial neurotrophic factor and method for producing the same | |
CN101773595B (en) | Herbal tea for clearing liver and improving eyesight | |
CN102965235B (en) | Chinese chestnut health preserving wine | |
CN107549554B (en) | Fruit juice fermented beverage with beautifying and freckle removing functions and preparation method thereof | |
US20060140974A1 (en) | Method for selectively inhibiting reuptake of serotonin and norepinephrine using yeast extract | |
KR101205516B1 (en) | Use of arachidonic acid for normalization of infradian rhythm | |
CN109820905A (en) | A kind of pharmaceutical composition and its application for treating insomnia | |
CN105639560A (en) | Biological-enzymolysis-method sporoderm-broken lucid ganoderma spore powder honey for calming nerves and aiding sleep and production process thereof | |
KR100487887B1 (en) | East extract relaxing premenstrual sydrome and menstrual pain, compositions containing the same, and preparation thereof | |
US8715650B2 (en) | Bathing composition and method for preparing same | |
WO2008014256A2 (en) | Composition including superoxide dismutase and prickly-pear cactus for minimizing and preventing hangovers | |
CN105250199A (en) | Edible facial mask containing pearl powder | |
CN110710678A (en) | Marine polypeptide donkey-hide gelatin paste capable of nourishing liver and kidney, nourishing blood and soothing nerves and preparation method thereof | |
CA2898686A1 (en) | Food supplement for people with down syndrome, autism spectrum disorders and/or attention deficit disorder with or without hyperactivity | |
CN116235954A (en) | Sleep-aiding probiotic composition and preparation method thereof | |
CN116076710A (en) | Rose herbal ferment with anti-aging and whitening functions and preparation method and application thereof | |
CN101703249A (en) | Health care product with functions of regulating incretion and increasing immunity and preparation method thereof | |
JP2020188755A (en) | Food composition for improving brain function, brain function improver, food composition for enhancing brain-derived neurotrophic factor, food composition for suppressing stress hormone excretion, enhancer of brain-derived neurotrophic factor and stress hormone excretion suppressor | |
CN111972664A (en) | Health-care capsule | |
CN111493314A (en) | Food material nutrient with bioactive substances and solid beverage | |
CN107960469A (en) | A kind of pearl milk powder for improving sleep and preparation method thereof | |
CN109363164A (en) | A kind of oral solution and preparation method thereof containing small-molecular peptides that can improve microcirculation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20090427 Year of fee payment: 5 |
|
LAPS | Lapse due to unpaid annual fee |